The impact of mitochondria on cancer treatment resistance

Area of Science:

• Mitochondrial biology
• Cancer research
• Metabolic reprogramming

Background:

• Cancer cells develop treatment resistance, a major obstacle to successful therapy.
• Mitochondria, once considered dysfunctional, are now recognized as critical mediators of cancer progression and treatment resistance.
• The precise mechanisms by which mitochondria confer treatment resistance remain incompletely understood.

Purpose of the Study:

• To elucidate the mechanisms by which mitochondria promote cancer treatment resistance.
• To explore the potential of targeting mitochondria as a strategy to overcome treatment resistance.
• To investigate the utility of tumoral DNA analysis in guiding cancer treatment decisions.

Main Methods:

• Review of literature on mitochondrial function in cancer treatment resistance.
• Analysis of mutations in tricarboxylic acid (TCA) cycle enzymes and their downstream effects.
• Investigation of mitochondrial transfer from stromal cells to cancer cells.

Main Results:

• Mutations in TCA cycle enzymes (e.g., fumarate hydratase, isocitrate dehydrogenase) lead to oncometabolite accumulation (fumarate, 2-hydroxyglutarate).
• These oncometabolites can enhance treatment resistance by activating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, suppressing anti-tumor immunity, and promoting angiogenesis.
• Stromal cells can transfer functional mitochondria to cancer cells post-therapy, aiding resistance.

Conclusions:

• Mitochondria actively contribute to cancer treatment resistance through various mechanisms.
• Targeting mitochondria presents a viable strategy to combat treatment resistance.
• Tumoral DNA analysis can identify actionable mutations in TCA cycle enzymes, guiding personalized treatment strategies for improved outcomes, including enhanced efficacy of anti-angiogenic agents and immunotherapy.